



# *Voyageur Pharmaceuticals LTD*

## *From the Earth to the Bottle*

### **Assets & Production Partners Now in Place to Commence Revenue Generation**

Voyageur has created a unique business model in the radio-contrast pharmaceutical market. A strategy to control all input costs from mineral production to pharmaceutical drug manufacturing. Our focus is on Barium & Iodine radio-contrast media drugs. Initially we will use strategic agreements that will result in immediate sales in India, followed by North America and then worldwide sales. We have made excellent progress on these fronts.

### **Business Strategy to Create Near Term Cash Flow**

- Health Canada product registrations filed for barium radio-graphic contrast. All products are in final stage of Health Canada review and are expected to be granted imminently.
- Strategic partnership established with ThinQ, securing iodine supply that will enable Voyageur to generate near-term revenue with the potential to generate significant revenue as we expand. Strategic Agreement with ThinQ news Link: <https://voyageurpharmaceuticals.ca/voyageur-creates-strategic-agreement-with-thinq-for-future-drug-development/>
- ThinQ brings Voyageur scientific & drug formulation expertise and significant FDA regulatory experience. ThinkQ are a generic drug developer that manufactures 25 prescription drugs, with 30 drugs under development and 24 API's (Active Pharmaceutical Ingredients).
- FDA Applications for barium contrast part of Use of Proceeds. The FDA is being very cooperative as they want to ensure increased competition specifically in the USA barium contrast market (estimated total market of \$60 million annually).
- Iodine is vital to Voyageur's marketing strategy. For every bottle of barium sold, +20 bottles of iodine may be sold to the same customer. USA iodine market is \$1,500,000,000 per year.
- ThinQ has granted Voyageur the right to use their iodine formulations for our generic Iopamidol and Iohexal product lines. Regulatory submissions are planned for India, USA and Canada, with the Indian market having the shortest timeline. All submissions will be pursued as part of Use of Proceeds.
- Voyageur and ThinQ in negotiations with Indian contract manufacturing companies to begin sales immediately in India for iodine and barium contrast products. Sales estimated to begin within four-months in India after a deal is in place.
- To diversify our supply chain, Canada barium contrast manufacturing slated to begin upon approvals and future financing - using third party ingredients - and a third-party drug manufacturing company located in Calgary.



# ***Voyageur Pharmaceuticals LTD***

## ***From the Earth to the Bottle***

- Drilling results from Voyageur's Frances Creek barium project ("FC") show highest quality of barium sulfate globally (pharmaceutical grade) with an estimated supply of +40 years. FC is the only Non-Chinese qualifying deposit globally.
- Use of Proceeds will be applied to: Voyageur's FDA registration filing, fund the completion of PEA and Prefeasibility reports including the plant engineering, all within six months of the close of the current financing. Use of proceeds will also fund the launch of our partnership with ThinQ in the Indian market.
- Upon completion of prefeasibility study, a production pilot plant (API barium, Ba/Iodine contrast) will be built and a bulk sample completed from the FC quarry (currently planned Q2 2021) through additional financing.
- Voyageur internal projections show very robust economics that increase as the project progresses.

***Voyageur is implementing a strategy to begin cash flow using third party minerals and manufacturing. Upon completion of our full integration strategy, revenue and profits become robust with high growth rates over the long term, becoming the only fully integrated radio-contrast company globally. We expect cash flow in early 2021 that will begin with sales in the Indian marketplace as we continue to build out additional markets.***

***Thank you,***

***Brent Willis***

***CEO***

***Voyageur Pharmaceuticals Ltd.***